No­var­tis plans for po­ten­tial ac­cel­er­at­ed ap­proval for kid­ney dis­ease drug af­ter PhI­II in­ter­im analy­sis re­sult

No­var­tis’ rare kid­ney dis­ease drug, which it ac­quired in a $3.2 bil­lion pur­chase of Chi­nook Ther­a­peu­tics in June, met the pri­ma­ry end­point of a Phase III study af­ter an in­ter­im analy­sis, the com­pa­ny an­nounced Mon­day. 

Atrasen­tan, an oral en­dothe­lin A re­cep­tor an­tag­o­nist, demon­strat­ed “su­pe­ri­or­i­ty” against place­bo at a 36-week in­ter­im analy­sis in the 340-pa­tient ALIGN study in pa­tients with IgA nephropa­thy (IgAN), a pro­gres­sive and rare kid­ney dis­ease that large­ly im­pacts young adults. IgAN is a ma­jor cause of chron­ic kid­ney dis­ease and kid­ney fail­ure as it pro­gress­es.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER